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Objectives: Preclinical diagnosis of Parkinson’s disease (PD) is nowadays a topic of 
interest as the neuropathological process could begin years before the appearance of 
motor symptoms. Several symptoms, among them hyposmia, could precede motor 
features in PD. In the preclinical phase of PD, a subclinical reduction in motor skills is 
highly likely. In this pilot study, we investigate a step- by- step method to achieve pre-
clinical PD diagnosis.
Material and methods: We used the IOIT (Italian Olfactory Identification Test) to 
screen a population of healthy subjects. We identified 20 subjects with idiopathic hy-
posmia. Hyposmic subjects underwent an evaluation of motor skills, at baseline and 
after 1 year, using motion analysis sensors previously created by us.
Results: One subject showed significant worsening in motor measurements. In this 
subject, we further conducted a dopaminergic challenge test monitored with the same 
sensors and, finally, he underwent [123I]- FP/CIT (DaTscan) SPECT brain imaging. The 
results show that he is probably affected by preclinical PD.
Conclusions: Our pilot study suggests that the combined use of an olfactory test and 
motor sensors for motion analysis could be useful for a screening of healthy subjects 
to identify those at a high risk of developing PD.
K E Y W O R D S
Italian Olfactory Identification Test, Parkinson’s disease, Parkinson’s disease preclinical diagnosis, 
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1  | INTRODUCTION
It is widely accepted that the neuropathological process of Parkinson’s 
disease (PD) begins years before the appearance of motor signs. The 
preclinical phase of PD is believed to last 5- 8 years during which the 
neuropathological process has begun, but there is no clinical evidence of 
motor disturbances (tremor, bradykinesia, rigidity). Therefore, preclinical 
diagnosis of PD could be very important to test agents that could be truly 
neuroprotective and to better understand pathological history of PD.1,2
Definite criteria for preclinical diagnosis of PD are still lacking, so 
this is a topic of great interest and in constant evolution.3,4
The diagnosis of PD rests mainly on clinical criteria, although 
sometimes functional imaging of the nigrostriatal dopaminergic sys-
tem could be useful (ie single- photon emission computed tomogra-
phy—SPECT using [123I]- FP/CIT, a ligand of presynaptic dopamine 
transporter—DAT). Nevertheless, to achieve preclinical diagnosis, the 
use of such techniques seems to be mandatory, to confirm a subclini-
cal dysfunction of the nigrostriatal pathway.2-5
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Hyposmia is one of the symptoms that very often precede the ap-
pearance of cardinal motor symptoms of PD. Despite its high sensitiv-
ity, the specificity of hyposmia in predicting PD is quite low.5 For this 
reason, hypothesizing a mass screening to achieve preclinical diagno-
sis, combining detection of olfaction with [123I]- FP/CIT SPECT seems 
impractical, considering the cost and the invasiveness of the latter.5 
For this reason, there is an unmet need to find low- cost non- invasive 
screening techniques that could discriminate, among subjects with id-
iopathic hyposmia, those with a probable underlying initial neurode-
generative process, who could possibly undergo [123I]- FP/CIT SPECT 
brain imaging.5
In preclinical PD, there could be a progressive or step- like re-
duction in motor performances until the disease becomes clinically 
evident. This subclinical reduction in motor abilities might not be per-
ceived by the patient nor by the clinician.
Wearable devices for motion analysis 6-10 could be useful in de-
tecting a subclinical reduction in motor skills.
We presume that by studying a population of idiopathic hyposmia 
with this type of sensors,6,7 we could find a subgroup of individuals 
that worsen in motor performances in time. In this subgroup of hypos-
mic individuals, we also could expect a response to dopaminergic drug 
challenge using our wearable devices to monitor the changes in mo-
tion parameters. We also think that many individuals in this subgroup 
should have positive results in [123I]- FP/CIT SPECT brain imaging.
Given these hypotheses, we did a pilot study and here we show 
the results.
2  | MATERIALS AND METHODS
A population of healthy subjects aged 60- 69 was recruited and under-
went an idiopathic hyposmia screening starting with a standardized 
smell test. With this first step, we identified 20 idiopathic hyposmic 
subjects of 287 healthy subjects.
Exclusion criteria in recruitment were as follows: a MMSE 11 score 
<27; history of previous concussive head trauma; previous or pres-
ent neurological or psychiatric disease; major otolaryngological, or-
thopaedic, rheumatological or oncological diseases; major metabolic 
diseases; hyposmia with known aetiology.
Olfaction was tested with IOIT.12	Individuals	with	an	IOIT	score	≥7	
were considered hyposmic and underwent neurological examination, 
an otolaryngological visit, and a basal magnetic resonance imaging 
(MRI) scan of the brain. We did not consider minimal vascular lesions 
in MRI as an exclusion criterion. Hyposmia was considered idiopathic 
if there was no known cause and if none of the exclusion criteria were 
present.
During the first evaluation, subjects with idiopathic hyposmia un-
derwent a measurement of 4 motor tasks using inertial sensors suit-
able for the study of upper and lower limb movements.6,7
Motor parameters evaluated: (i) number of thumb- middle finger 
tappings (THMF); (ii) number of movements in hand opening- closing 
task (OPCL); (iii) number of movements in hand prono- supination 
task (PSUP); (iv) variability of tiptoe tapping task (TTFCV) calculated 
as follows: (maximum frequency – minimum frequency)/maximum 
frequency × 100.
Each of the previous tasks was executed for 10 seconds 3 times 
each, measuring all of them. The results were the mean of the 3 
measurements.
One year after recruitment, each subject with idiopathic hyposmia 
underwent neurological examination and measurement of motor per-
formances with the same sensors again. We evaluated each subject 
for the possible appearance of neurological signs, and we considered 
the per cent variation of motor performances between the 2 measure-
ments, at 1 year of distance.
Given the absence of normative data and cut- off values for motor 
measurements, in this study we decided to consider every subject with 
idiopathic hyposmia that we assessed as a reference point for himself 
in the motor measurements conducted in time.
For the aim of our study, a worsening that was not due to drugs, 
neurological diseases or other pathological conditions that could 
change motor skills and joints functions were considered relevant.
To choose the degree of subclinical worsening that could imply 
a preclinical PD, we deduced from clinical experience a percentage 
worsening of motor measurements beyond which preclinical PD was 
suspected. We considered a subclinical idiopathic worsening greater 
than 15% in at least 2 motor tasks as a warning sign for preclinical 
PD.
The clinical reasoning which prompted us to choose this cut- off 
value is the following: in patients with PD, Horváth et al13 estimated 
the minimal clinically important difference (MICD) in worsening (mean 
PD patients’ MDS- UPDRS III score = 40.7 and threshold for MCID to 
detecting worsening + 4.63 points) which, expressed in percentage, 
corresponds to the 11.38%. Having this in mind, we tried to adopt 
a per cent value of subclinical reduction in motor skills avoiding an 
overestimation of hyposmic subjects with possible preclinical PD. 
Therefore, we opted for a cut- off percentage of worsening higher than 
the one selected by Horváth et al.13 We considered a subclinical id-
iopathic worsening greater than 15% in at least 2 motor tasks as a 
warning sign for preclinical PD.
We carried out a dopaminergic challenge test only in hyposmic 
subjects, with negative neurological examination, which showed a 
worsening >15% in 2 or more motor parameters (unilaterally or on 
both sides) over time.
As there are no previous data on the dopaminergic challenge test 
in the preclinical phase of PD, on the base of clinical reasoning we 
chose the cut- off percentage of subclinical improvement of motor 
measurements during dopaminergic stimulus suggestive of a positive 
response to the test itself.
The clinical reasoning which prompted us to choose this cut- off 
value is the following: the acute dopaminergic challenge test is gener-
ally considered positive, in drug- naïve patients with PD, when an im-
provement >20% is observed.14 In a chronic test, the response could 
even be >30%.15 Some authors consider this cut- off value too high, 
especially in very early patients with PD.16
Horváth et al13 observed that the MICD of MDS- UPDRS III 
score to detecting improvement is + 3.25 points and expressed as 
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a percentage is 7.99% (considering the mean of PD patients’ MDS- 
UPDRS III scores = 40.7).
We adopted a percentage cut- off value of improvement at 
levodopa (L- Dopa) challenge test, which was approximately between 
the cut- off value in the acute L- Dopa challenge test (20%) and the per-
centage of MICD improvement (7.99%) according to Horváth et al.13
A subsequent worsening in motor measurements after stopping 
L- Dopa may be considered a further sign of a preclinical PD.
2.1 | Dopaminergic challenge test
L- Dopa dosage was gradually increased over several days, so that 
the day before the objective measure of motility (14th), the dose is 
200 mg tid and the day of the measurement (15th), the dose is 200 mg 
of L- Dopa (taken 45 minutes before the test). Then, the dosage was 
gradually reduced until it was withdrawn.
Objective measurements of movements were conducted at T0 be-
fore prescribing L- Dopa, at full dopaminergic dosage (T15) and at day 
30, when L- Dopa was stopped (T30); (Table S1).
For the evaluation of dopaminergic challenge test, we considered 
the per cent change of motor measurements at T15 compared with T0 
and T30 compared with T15.
An improvement of >15% at T15 of the motor measurements 
which showed a reduction at T0 was considered as a positive result; a 
further worsening of the same parameters at T30 was also considered 
as a positive result.
Only hyposmic individuals who tested positive at dopaminergic 
challenge test underwent [123I]- FP/CIT SPECT.
2.2 | Additional investigations
Furthermore, we analysed a control group of healthy subjects, matched 
by sex and age with the hyposmic subjects. Each subject underwent 
a first detection of motor tasks (THMF; OPCL; PSUP; TTFCV), which 
was repeated after 3 days. The results of the second and the first ob-
jective measurements were compared (test- retest challenge) using 
Pearson’s linear correlation coefficient.
The comparison of the motor measurements recorded at the first 
detection in the group of hyposmic subjects and in the healthy control 
group was performed using by t test for independent sample and with 
Mann- Whitney rank test as appropriate.
The differences between motor performances (Delta value right- 
left) of right limbs and the ones of left limbs were recorded, taking into 
consideration the first measurement in healthy control subjects and 
the first measurement in hyposmic subjects.
Our study was approved by the Ethical Committee of Massa and 
Carrara Local Health Institution with the following reference: No. 311, 
11/18/2010. Informed consent was obtained from all individual par-
ticipants included in the study.
3  | INSTRUMENTS
The wearable devices used for the evaluation and analysis of motor 
parameters are the inertial sensor systems SensHand v1 and SensFoot 
v2 (Figure 1), which were appropriately developed for this application. 
An Inertial Measurement Unit (IMU) integrated in the iNEMO- M1 
board based on MEMS sensors (3- axis gyroscope L3G4200D and 6- 
axis geomagnetic module LSM303DLHC) and ARM microcontroller 
STM32F103RE (STMicroelectronics, Milano, Italy) was used to de-
velop the SensFoot v2 device for lower limbs analysis. The device is 
placed on the dorsum of subject’s foot within an elastic band to en-
sure the integrality between foot and sensor. SensHand v1, instead, is 
composed of 4 customized elements with 1 coordination unit included 
in a bracelet and 3 finger units placed in as many ring packages for 
thumb, index and middle finger. The bracelet and the 3 rings communi-
cate by means of spiral cables exploiting the Controller Area Network 
(CAN- bus) standard. Both the controller and the finger boards are 
equipped with the STM32F103REY6TR High- density ARM- based 32- 
bit Microcontroller (MCU); (STMicroelectronics, Milano, Italy) and a 
complete 9DOF IMU is composed of the LSM303DLHC e- compass 
3D accelerometer and 3D magnetometer module and the L3G4200D 
triaxial gyroscope (STMicroelectronics, Italy) that guarantee the map-
ping of motion in the 3- dimensional space.
In both systems, inertial sensor signals are acquired at a fre-
quency rate of 100 Hz. They are supplied by a rechargeable LiPo 
battery and integrated with Bluetooth module (SPBT2632C2A, v3.0; 
STMicroelectronics) which wirelessly transmits data acquired to re-
mote personal computer (PC) for offline analysis. The coordination 
unit synchronizes the data exchange between the nodes of the de-
vice and establishes a Bluetooth wireless communication towards a 
PC station, where a graphical user interface is used by neurologists 
FIGURE 1 SensHand v1 and SensFoot v2
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for storing data and to analyse the motion parameters evaluated. 
SensHand v1 and SensFoot v2 were designed as a small and light 
structure that is easy to wear and to use, regardless of the physical 
build of the person wearing it and from variations caused by move-
ment. Preliminary studies on accuracy reveal that these wearable 
devices have minor discrepancies (coefficient of correlation > 0.9; 
data not yet published) when the measurements are compared 
with those obtained with a stereophotogrammetry system (BTS 
Bioengineering).
Furthermore, the system is not affected by problems related to 
the deterioration of the sensors and it does not require frequent 
calibration thanks to the type of sensors, which provide an intrinsic 
compensation typical of triaxial systems. As for additional proper-
ties, the system is characterized by low- cost components and low 
power consumption as well as long life thanks to low liability to 
deterioration.
4  | RESULTS
We screened 287 healthy subjects; 20 of them were chosen be-
cause they had idiopathic hyposmia (12 men, 8 women, mean age 
67.1 ± 2.48).
Of 287 subjects selected, we identified 3 cases of mild nasal pol-
yposis and 2 cases of hyposmia following influenza- like infection. 
These persons have been excluded from our study.
After 1 year, all our hyposmic subjects still had a negative neuro-
logical examination. Furthermore, after 1 year, 19 of 20 showed slight 
motor measurement changes (mean values in Table 1. All the values in 
Table S2A, B).
One 64- year- old, right- handed and non- smoking male, although 
still negative at the neurological exam (Video S1), showed a deterio-
ration greater than 15% in 6 of the 8 parameters analysed (Table 1. All 
the values in Table S2A, B).
The dopaminergic challenge test with L- Dopa conducted in this 
subject showed an improvement larger than 15% in all the 6 param-
eters that had previously deteriorated at the 1- year follow- up. A new 
deterioration in these parameters became evident after the discontin-
uation of the drug (Figure 2. All the values in Table S3).
Eventually the [123I]- FP/CIT SPECT brain imaging of this subject 
showed a reduction in the uptake of the ligand bilaterally in the striata, 
with a prevalence on the right side (Figure 3).
A test- retest trial conducted on healthy control subjects showed 
a good correlation of objective motor measurements obtained in both 
measurements (P- value < .01) (Tables S4 and S5).
We did not find statistically significant differences in performance 
between hyposmic subjects and healthy control subjects.
The analysis of the difference in motor performances between right 
and left limbs showed that healthy subjects performed slightly better 
with their right limbs (faster movements of the hand and less variability of 
toe tapping). These results have also been obtained in hyposmic subjects 
with the exception of a broader variability in toe tapping (Table S6).
TABLE  1 Motor measurements detected at enrolment and after 1 y in subjects with idiopathic hyposmia
Side Motor task Time measurement
Motor measurements detected in the 19 
hyposmic subjects who showed 
changes < 15% after 1 y Motor measurements detected in the 
subject who showed changes > 15% 
after 1 yMean SD
Right THMF At enrolment 44.63 6.66 50.00
THMF After 1 y 44.65 7.42 48.00
OPCL At enrolment 32.78 6.61 36.67
OPCL After 1 y 32.60 6.71 33.33
PSUP At enrolment 23.34 6.02 25.32a
PSUP After 1 y 23.05 5.93 17.00a
TTFCV At enrolment 34.94 9.47 20.85a
TTFCV After 1 y 34.83 9.33 37.16a
Left THMF At enrolment 42.26 6.29 42.33a
THMF After 1 y 42.00 6.86 35.67a
OPCL At enrolment 31.71 7.00 34.67a
OPCL After 1 y 31.28 6.72 29.33a
PSUP At enrolment 21.21 5.67 22.67a
PSUP After 1 y 20.97 5.33 18.31a
TTFCV At enrolment 29.41 9.07 22.65a
TTFCV After 1 y 29.64 8.29 44.11a
THMF, Thumb- Middle Finger Tapping (number); OPCL, Hand opening- closing (number); PSUP, Hand pronation- supination (number);.TTFCV, Toe Tapping 
frequency- coefficient of variation: the higher the value less regular is the movement execution.
aMotor measurements that showed a per cent variation greater than 15% at one- year follow- up visit.
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5  | DISCUSSION
Using the inclusion/exclusion criteria adopted for our study, we ex-
cluded cases of olfactory dysfunction related to several clinical condi-
tions such as cognitive decline, history of previous concussive head 
trauma; major otolaryngological, rheumatological, metabolic diseases, 
malignancies. Indeed, the present study is not meant to estimate 
the prevalence and causes of olfactory dysfunctions in the general 
population.
Several devices for the analysis of human motion have been de-
veloped in recent years, suitable for objective motor measurements 
and for discrimination between normal motor patterns and PD 
 patterns.6-10 The use of objective measurements for motricity could 
improve the reliability of motor evaluation of PD patients, reducing 
the subjective differences that clinical evaluation with motor scales 
implicate, with evaluation conducted by different operators over 
time17. Nevertheless, the actual use of these tools in daily clinical prac-
tice is still limited due to the lack of normative data from the motor 
F IGURE  2 Dopaminergic challenge test 
carried on in the idiopathic hyposmic subject 
with possible preclinical PD (per cent variation 
of motor measurements during the different 
phases of the test)
F IGURE  3  123I- FP- CIT SPECT (123I- ioflupane) of the subject with possible preclinical PD
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measurements and of validated clinical scales that use this type of 
motor measurement.
Normative data and cut- off values for the measurements of motor 
items in PD evaluations could be very useful in studies on preclinical 
PD diagnosis: subjects with borderline values in motor measurements 
could be considered at high PD risk.
Nowadays, it is possible to measure with precision, with wireless 
technology, certain body movements, among which are those useful 
for clinical evaluation of patients with PD.
Motor measurements obtained with the sensors used in the pres-
ent study showed high correlation coefficients in a test- retest proof 
carried out on a group of healthy control subjects.
We designed a pilot study on preclinical PD diagnosis using objec-
tive measurements even in the absence of normative data and cut- off 
values.
In this study, given the absence of such normative data in litera-
ture, we decided to consider every subject with idiopathic hyposmia 
(therefore at high risk of developing PD) that we assessed as a ref-
erence point for himself in the motor measurements conducted over 
time. We hypothesize that a subject with preclinical PD may have a 
subtle reduction in motor performances over time until motor abnor-
malities become clinically evident.
Given the absence of previous references in literature and to 
choose the degree of subclinical deterioration that might imply a pre-
clinical PD, we deduced from clinical experience a per cent deteriora-
tion of motor measurements beyond which would infer preclinical PD 
(see Materials and Methods). We considered a subclinical idiopathic 
deterioration greater than 15% in at least 2 motor tasks as a warning 
sign for preclinical PD.
A per cent variation >15% of motor measurements after 1 year, 
chosen as cut- off values for motor deterioration after 1 year, cannot 
be explained with the variability of objective measurements consid-
ering also the very low variability within each subject for each mea-
surement (maximum observed SD was 0.44) emerged in the rigorous 
experimental setting.
The question of repeatability of measures can be further studied to 
a wider range of subjects.
The choice of a cut- off value >15% for motor measurements obtained 
using our precise sensors requires further confirmation on broader pop-
ulations. Nevertheless, we believe it is a starting point to detect changes 
over time of motor patterns that could be attributable to biological varia-
tions and not only to a mere variability in motor measurements.
We believe that normative data should not be deduced from a 
small sample like the one shown in our study.
We did not find statistically significant differences in performance 
between the group of hyposmic subjects and that of healthy control 
subjects. Perhaps this depends on the small sample of population 
studied or by the limited number of motor tasks taken into account, 
but most probably because, as it is well known in literature,5 most peo-
ple with idiopathic hyposmia do not have a preclinical PD.
With broader populations, it will be possible to analyse the role 
of age, gender, laterality on upper and lower limbs on motor perfor-
mances, developing solid, normative data.
The lateralization of the motor control should be carefully in-
vestigated; in fact, there are several persons who use both hands 
(or feet) in variable percentage depending on the task they are 
doing. In addition, lateralization can be discordant in upper and 
lower limbs.
Subjects in our study, all right- handed, showed better motor per-
formance with right limbs than with left limbs and this is in line with 
previous literature about finger tapping.18
Also, the hyposmic subject with possible preclinical PD demon-
strated better performance in tasks using right limbs. Nevertheless, the 
small sample we analysed does not allow for the establishment of which 
value of right/left asymmetry could be considered normal and which 
value could be considered as a cut- off for potential preclinical PD.
Strong normative data would be necessary for using the difference 
in motor performances between right and left limbs as a parameter 
in studies on preclinical diagnosis. Possible combinations of laterality 
in upper and lower limbs should be taken into consideration, as there 
could be discrepancy between them. Side preference could be variable 
in different subjects.
With consideration to the side displaying the onset of PD, there 
could be several possible combinations of motor performance differ-
ences between left and right side that might increase or decrease in 
various ways.
Finally, it cannot be ruled out that in atypical parkinsonism, where 
bradykinesia is often bilateral, the difference in performance between 
right and left limbs tends to remain quite stable, despite the disease 
being slowly progressive.
In our present work, we have adopted a different approach: every 
subject is a reference for himself for possible changes in motor perfor-
mances over time.
After a one- year follow- up, only one of the 20 subjects with idio-
pathic hyposmia showed a subclinical idiopathic deterioration in their 
motor measurements >15%. This subject presented a deterioration of 
all motor indexes measured in left limbs (3 on the upper limb and the 
1 on the lower) and of 2 motor indexes in right limbs (1 on the upper 
limb and the 1 on the lower). This asymmetry resembles what clini-
cians usually observe in clinically evident PD.
[123I]- FP/CIT SPECT is quite invasive and expensive so to limit the 
number of hyposmic subjects in our population that should undergo 
this examination, we decided to carry out a dopaminergic challenge 
test in patients with deterioration of motor measurements over time.
SensHand v1 & SensFoot v2 6,7 inertial sensors were used also to 
monitor the dopaminergic challenge test.
We opted for an extended dopaminergic challenge test as the 
acute one often implicates noteworthy side effects.16
We evaluated the response to dopaminergic stimulus with a pro-
longed 15- day test. We did not consider a longer- lasting test to be 
necessary (chronic test of several months) as the response could be 
expected within a shorter timescale.
On the basis of clinical reasoning, we chose the per cent cut- off 
of subclinical improvement of motor measurements, during dopami-
nergic stimulus, suggestive of a positive response to the test itself 
(see Materials and Methods). The per cent value of improvement that 
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we chose as a cut- off for the dopaminergic challenge test (>15%) is 
arbitrary but reasonable and it needs confirmation within broader 
populations.
A subsequent deterioration in motor measurements after stopping 
L- Dopa may be considered a further clue of preclinical PD.
Only the above- mentioned subject underwent a dopaminergic 
challenge test using wearable devices to monitor the changes in mo-
tion parameters.
The pharmacological test showed an improvement greater than 
15% in motor measurements that were previously lowered in this sub-
ject and we also observed a deterioration after the discontinuation of 
L- Dopa. These changes during pharmacological stimulus strengthened 
the suspect of preclinical PD in this subject.
According to our protocol, it was only this subject that underwent 
[123I]- FP/CIT SPECT. The result was in accordance with the hypothe-
sis of an initial neurodegeneration in dopaminergic nigrostriatal path-
ways. We therefore believe that the subject we identified may have 
preclinical PD according to [123I]- FP/CIT SPECT and to the previous 
screening steps.
In a preceding study by Berendse and Ponsen,5 all subjects with 
idiopathic hyposmia underwent [123I]- FP/CIT SPECT without further 
screening tests. All the hyposmic subjects with a positive [123I]- FP/CIT 
SPECT developed PD within 5 years. Nevertheless, about 80% of the 
hyposmic subjects had negative results in [123I]- FP/CIT SPECT and did 
not develop the disease.
According to the same authors,5 a good set of preclinical diagnosis 
should include more screening techniques to be administered for high- 
risk individuals (ie with idiopathic hyposmia), before considering [123I]- 
FP/CIT SPECT. We agree with this vision, and with our pilot study, 
we tried to develop a good screening set for subjects with idiopathic 
hyposmia to identify the individuals that should undergo [123I]- FP/CIT 
SPECT.
We believe that the subject we identified with our screening set is 
likely to be affected by preclinical PD. We will only be able to observe 
whether this individual will develop PD or parkinsonism with further 
follow- up appointments. We underline some limitations to our work. 
Cut- off values for suspected preclinical PD, as well as the cut- off val-
ues of the dopaminergic challenge test, were chosen by us arbitrarily 
using logical and clinical suppositions. So, these values need validation 
in subsequent works with broader populations.
Therefore, because of the arbitrary choice of cut- off values, there 
may be some of the idiopathic hyposmic subjects with preclinical PD 
in our population that will not develop a deterioration >15% in motor 
performances in 1 year or, less probably, will not show any deterio-
ration at all. It is possible that the cut- off values we used may cause 
some “false negatives.”
To estimate all the false negatives, all the hyposmic subjects should 
undergo [123I]- FP/CIT SPECT, but this is not in line with our study 
protocol. The follow- up of this sample will give some information on 
this topic over time.
We cannot exclude the fact that the cut- off value we chose could 
include some “false positives.” For example, a subject with idiopathic 
hyposmia with a deflection of motor measurements greater than 15% 
and a positive response to the dopaminergic challenge test (>15%) 
may not always have a positive response to [123I]- FP/CIT SPECT. 
Furthermore, a subject who showed a deterioration >15% in 1 year 
could have a negative result in the L- Dopa challenge test, although 
in this case it may also be atypical parkinsonism. Further studies are 
necessary to reduce these limitations.
As to the L- Dopa challenge test, the cut- off value we adopted has 
been chosen following a clinical reasoning. We believe that lowering 
this value (15%) could cause an increase in false- positive results.
Smaller L- Dopa dosages could be equally useful in detecting re-
sponse to the dopaminergic challenge test in subjects with probable 
preclinical PD. L- Dopa dosage and its administration times could be 
changed in future studies.
If all subjects with idiopathic hyposmia would undergo a L- Dopa 
challenge test, maybe we could make a distinction between them on 
the basis of per cent response at the test, detecting those with possi-
ble preclinical PD. But this choice would expose healthy people to a 
drug, even if for a short period.
For this reason, we preferred a more cautious strategy, proposing 
a pharmacological test only to hyposmic subjects with a deterioration 
in motor performance >15% in 1 year.
For technical reasons, we have used a limited number of motor 
measurements. In the lower limbs, we studied the variation in move-
ment frequency instead of its simple frequency, in this way hoping to 
obtain a more sensible index to detect variations of performances in 
time. We have to say, however, that this measure was the most vari-
able one. In upper limbs, as we have more measures of frequency of 
movements, we decided to study the more steady index.
This not homogeneity in adopted measures for upper and lower 
limbs could be a limit to overcome. So, to use further measurements 
in a clinical- experimental setting, we must make further efforts to 
develop new algorithms and improve some important details such as 
battery life and the autonomy of the instrument. That is why we are 
aware that a greater number of motor measurements could be used in 
future studies.
In addition, it is known that “a decrease in the duration of the first 
step when visual cues are present” 19 could be a potential predictor of 
freezing of gait in PD. This parameter, such as the different phases of 
gait, should be carefully analysed in future studies in the preclinical 
diagnosis of PD.
The above- mentioned limitations in relation to our study are al-
most unavoidable according to us, as ours is a pilot study in a new field 
of research: the preclinical diagnosis of PD. We believe that this field 
will be constantly updated.2-5
In the future, other variables may be taken into consideration in 
the selection of subjects at risk of developing PD. Several patients in 
the early phase of PD have a mild cognitive impairment20; therefore, a 
subject with idiopathic hyposmia and MCI could be at a higher risk of 
PD and thus be seen as a possible candidate to be monitored over time 
for motor measurements.
To conclude, over time many improvements may be added, but we 
believe that the set of screening tests we adopted in this pilot study 
(olfactory test, motor measurements carried out with inertial sensors 
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with their follow- up, and a dopaminergic challenge test monitored 
with the same sensors) is suitable to detect those hyposmic subjects 
who should undergo an expensive and invasive test like [123I]- FP/CIT 
SPECT with a high likelihood of a positive result.
In this study, we do not conclusively demonstrate the validity of 
our work hypothesis in diagnosing preclinical PD, as this was not the 
aim of this pilot study. However, the emerging results in this pilot 
study strongly support the idea that the combined use of an olfactory 
test and sensors for motion analysis could be very useful for screening 
aimed at identifying individuals with preclinical PD.
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